Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug for brain tumors tested in everyday clinics

NCT ID NCT07240662

Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 150 adults with slow-growing IDH-mutant grade 2 gliomas who are taking vorasidenib after surgery. Researchers will track quality of life, seizures, and tumor response in routine German clinics. The goal is to see how well the drug works outside of strict trial settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vorasidenib (oral drug)
What this could lead to
If successful, this study could show how vorasidenib affects daily life and seizures in real-world settings, guiding better care for glioma patients.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary and won't confirm long-term benefits or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jan 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (at least 40 kg) with predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * WHO grade 2 astrocytoma or oligodendroglioma * Presence of IDH1- or IDH2-mutation * Surgical intervention * No immediate need of radiotherapy or chemotherapy according to the treating physician * Decision for treatment with vorasidenib as per current SmPC * Signed written informed consent\* * Willingness to participate in Patient-Reported Outcome (PRO) assessment in German language * Other criteria according to current SmPC \* Patients are allowed to be enrolled up to 6 weeks after their first intake of vorasidenib but must still be on treatment at the time of enrollment Exclusion Criteria: * Participation in an interventional clinical trial * Patient unable to consent * Other contraindications according to current SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2 glioma grade II glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

    RECRUITING

    Heidelberg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.